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Cancer-associated thromboembolism is a substantial problem in clinical practice. An increase in the level of fibrinopeptide A
(a substance associated with hypercoagulable states) has been observed in humans exposed to fluorouracil. Anti-EGFR mono-
clonal antibodies cetuximab and panitumumab, which are now widely used in patients with metastatic colorectal cancer, could
prolong the uncovering of endothelial structures resulting from flouorouracil or other co-administered agents, thus favouring
several factors leading to thromboembolism. We performed a systematic review and meta-analysis of randomised, controlled
trials assessing whether cancer patients receiving anti-EGFR monoclonal antibodies cetuximab and panitumumab are at
increased risk of thromboembolic events. We searched electronic databases (Medline, Embase, Web of Science, Central) and
reference lists. Phase II/III randomised, controlled trials comparing standard anti-cancer regimens with or without anti-EGFR
monoclonal antibodies and reporting serious venous thromboembolic events were included in the analysis. Seventeen studies
(12,870 patients) were considered for quantitative analysis. The relative risk (RR) for venous thromboembolism (18 compari-
sons) was 1.46 (95% CI 1.26 to 1.69); the RR of pulmonary embolism, on the basis of eight studies providing nine compari-
sons, was 1.55 (1.20 to 2.00). Cancer patients receiving anti-EGFR monoclonal antibodies-containing regimens are
approximately 1.5 times more likely to experience venous or pulmonary embolism, compared to those treated with the same
regimens without anti-EGFR monoclonal antibodies. Clinicians should consider patient’s baseline thromboembolic risk when
selecting regimens that include cetuximab or panitumumab. Potential non-reporting of these important adverse events
remains a concern. PROSPERO registration number is CRD42014009165.
Introduction
Cancer patients have an acquired thrombophilic condition
predisposing them to thromboembolic events, which increase
morbidity, mortality and economic burden.1,2 The relation-
ship between malignancy and thromboembolism has been
demonstrated in many epidemiological studies with venous
thrombosis occurring in 4–20% of patients with cancer.3 The
annual incidence ranges from 0.5% to over 1%, compared to
0.1% in the general population.4 Overall, cancer patients con-
stitute 15–20% of the patients diagnosed with venous throm-
boembolism.5 Venous thromboembolic events (VTE) and
thrombotic complications have been listed as the second
most frequent cause of death in patients with cancer5,6, with
1-year survival of cancer patients diagnosed with VTE
reported as one third that of cancer patients without VTE
(matched for age, sex, type, and duration of the malignancy)
in a registry study.4
Thromboembolic events may present as a range of conditions
including deep vein thrombosis (DVT), pulmonary embolism
(PE), nonbacterial thrombotic endocarditis, superﬁcial thrombo-
phlebitis, catheter-related thrombosis, hepatic veno-occlusive dis-
ease, and also arterial thrombosis, each of which frequently
require long-term anticoagulation therapies and interruption of
chemotherapy.6–8
The hypercoagulable state in cancer involves various com-
plex interdependent mechanisms, including interaction
among cancer cells, host cells, and the coagulation system.
Cancer patients are also subject to non-oncologic risk factors
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of thromboembolism including: surgical interventions, immo-
bilization, infections, and, in particular, drug exposure may
greatly amplify the overall risk at various time points.9 Several
systematic reviews have explored the magnitude of this risk
associated with various anti-cancer agents such as cisplatin,
thalidomide, or novel therapies such as anti-angiogenic agents
targeting vascular endothelial growth factor receptor (EGFR).
However, to date, the knowledge on the potential impact of
many anti-cancer drugs on thromboembolism is limited.5
Cetuximab and Panitumumab, a chimeric and a fully
human monoclonal antibody, respectively, are two anti-EGFR
agents with demonstrated efﬁcacy as anti-cancer agents10,11
which are now incorporated routinely into several therapeutic
regimens. These monoclonal antibodies (MoAbs) bind to the
epidermal growth factor receptor (EGFR), a member of the
ErbB family which is constitutively expressed in many nor-
mal epithelial tissues and expressed at high levels in about
one third of epithelial cancers. Its activation appears to be
critical for the growth of many tumors.12 Anti-EGFR MoAbs,
block interaction of EGF with its speciﬁc receptor in both
tumour and normal cells, inhibiting receptor phosphoryla-
tion. This results in down-regulation of EGF receptors and
modulation of pivotal processes impacting on tumour growth
and progression such as angiogenesis, induction of apoptosis,
tumour invasiveness and metastatic spread.13,14 For these rea-
sons, EGFR is considered as a prominent therapeutic target
for MoAbs-based immunotherapy in cancer.15,16
The anti-EGFR antibodies cetuximab and panitumumab
are effective in different lines of treatment and in several com-
binations in the management of neoplasia such as colorectal
cancer. Although beneﬁcial, these agents have been associated
with increased incidence of severe harms including skin rash,
electrolyte abnormalities, especially magnesium-wasting syn-
drome, haematological disorders, infusion reactions and
thromboembolic events.17,18
To the best of our knowledge, the only systematic review
examining the risk of thromboembolism was published in
2012.19 In this analysis events occurring in patients treated
with anti-EGFR antibodies and EGFR-Tyrosine kinase inhibi-
tors were combined. Anti-EGFR antibodies and EGFR-
Tyrosine kinase inhibitors belong to two distinct classes of
anti-EGFR drugs with different pharmacokinetic and phar-
macodynamic properties and, conceivably different safety
proﬁles20, thus it appears more appropriate to analyse them
separately.
As the indications for use of anti-EGFR monoclonal anti-
bodies are increasing, we carried out an updated and compre-
hensive systematic review that focuses speciﬁcally on cetuximab
and panitumumab to better deﬁne their patterns of vascular tox-
icity in cancer patients. We also explored potential differences in
the relationships between different cancers and type of MoAbs
with the aim of providing clinicians with solid evidence on which
to plan therapies and optimize risk management strategies.
Methods
Aims and objective
To assess the potential risk of developing severe thromboembolic
AEs in cancer patients treated with cetuximab or panitumumab
combined with standard therapeutic regimens.
Protocol registration
As recommended by the PRISMA statement and more
recently PRISMA-P21,22 all planned review methods were
speciﬁed in a protocol which was registered on PROSPERO
(http://www.crd.york.ac.uk/PROSPERO: CRD42014009165).
Information sources and searching
Medline, Embase, Central, Web of Science and the WHO plat-
form for Clinical Trials were searched from inception until 1st
October 2014. The base search strategy was constructed using
Medline and then adapted to the other resources searched. We
also carried out a manual search of the bibliographies of rele-
vant studies. A complete literature search strategy is reported in
Supporting Information Appendix (Online extra). An update
of literature search was performed in April 2016 to implement
most recently released data in our analyses.
Inclusion criteria
Prospective phase II or III randomised controlled trials com-
paring a standard regimen plus anti-EGFR monoclonal anti-
body with the same standard regimen alone in cancer patients
were eligible for inclusion. Studies written in English and
reporting data on the number of thromboembolic adverse
events (AEs) were considered. Phase I trials, single-arm phase
II or III trials, trials comparing different backbone regimens
with anti-EGFR MoAbs were excluded (Fig. F11).
Data collection
Data were extracted independently by two investigators (MM and
CS) with discrepancies resolved by consulting a third reviewer
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What’s new?
While monoclonal antibodies (MoAbs) targeting the epidermal growth factor receptor (EGFR) are effective anticancer agents,
their use is associated with an increased risk of severe thromboembolism, a condition to which some cancer patients are pre-
disposed. Nonetheless, the degree to which anti-EGFR MoAbs contribute to this risk was unclear. In this systematic review of
17 different studies, thromboembolic events were found to be 1.5 times more likely in cancer patients treated with anti-EGFR
MoAb-containing regimens than in patients given the same regimens but without MoAbs. Relative risk of thromboembolic
events did not vary significantly between cancer types.
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(GC). Multiple papers reporting the results of the same cohort
were handled by considering only the one reporting the largest
population. For each study, we extracted year of publication, trial
phase, treatment delivered on each arm, planned anti-EGFR
MoAbs doses, underlying malignancy, number of participants
enrolled, number of participants evaluable for safety analysis,
median age, median follow-up duration and type of thromboem-
bolic events of interest, including the number of VTEs and their
severity.
AEs were as reported by each trial, and deﬁned by criteria
established by the WHO, Cancer and Leukemia Group B, or
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE), Version 2 or 3.23,24 All
reported grade 3–4 thromboembolic AEs in each arm of
treatment were recorded and classiﬁed as deep venous
thrombosis (DVT), pulmonary embolism (PE), or unspeciﬁed
thromboembolism. As we planned to conduct a speciﬁc
analysis for PE, where study publications reported only a
combined thromboembolic AEs category, we contacted
authors to seek clariﬁcation of the number and type of
thromboembolic events that had occurred.
Risk of bias assessment
Two authors (MM and CS) independently evaluated risk of
bias using Cochrane Risk of Bias tool.25 This was modiﬁed
by removing the item on selective outcome reporting, as
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Figure 1. Flow diagram of the study selection process for the systematic review.
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reporting of the adverse events under investigation was an
inclusion criteria. Also, clinical studies having as primary
outcome effectiveness and not drug safety do not generally
provide sufﬁcient information to establish if selective report-
ing related to a speciﬁc AE occurred.
Statistical Analysis
We calculated the risk of Grade 3–4 VTE AEs by dividing
the number of patients experiencing DVT, PE or unspeciﬁed
thromboembolism AEs in each arm by the total number of
patients evaluated for toxicity. If the latter was not presented,
the total of patients enrolled in each arm was used as denom-
inator. The ratio of these risks was used to calculate relative
risk (RR) and the 95% conﬁdence interval for each AE con-
sidered. Computed values for each study were then combined
in meta-analyses using both ﬁxed-effects and random-effects
models.26 As very few thrombotic events were anticipated, we
used the Mantel-Haeszel method27 and logistic regression
modelling.28 For each meta-analysis, the Cochran Q test and
the I-squared statistic were calculated to estimate between-
trial heterogeneity.
We conducted sensitivity analyses to explore the inﬂuence
of the following factors on the size of the effect and on hetero-
geneity: co-administration of anti-angiogenic drugs (excluding
trials with bevacizumab-containing regimens), treatment expo-
sure (excluding trials with difference in drug exposure between
arms) and need of palliative treatment (excluding trials on
patients with advanced cancer requiring best supportive care).
Analysis of subgroups
Where data were available, pre-speciﬁed subgroup analyses were
performed to identify whether treatment effect was modiﬁed by
risk factors for severe thromboembolism. These included: under-
lying malignancy; antibody administered (cetuximab or panitu-
mumab) and anti-EGFR scheduled dose.
The overall effect estimate for each outcome was re-
expressed as Number Needed to Harm (NNH) across a range
of assumed control risks (ACRs) based on event rates in the
control arm of all studies.29 We calculated weighted mean inci-
dence with 95% CI of AEs using rates of the events observed in
experimental and control arms of the considered studies. Statis-
tical analyses were carried out using appropriate software,
including R, Review Manager, Microsoft Excel.
Results
Study identification and selection
Searches returned 6,777 records. Following de-duplication,
titles and abstract of 3,939 records were, screening resulting
in 248 potentially eligible studies. These underwent a full text
evaluation resulting in 15 randomised clinical trials (RCTs)
that fulﬁlled all inclusion criteria (Fig. 1).30–45 The literature
search update performed in April 2016 returned 635
additional records, that, after a literature selection process,
provided two clinical trials meeting inclusion criteria. We
contacted authors of nine relevant studies asking for further
data on thromboembolism (Supporting Information Appen-
dix). Four authors replied, unfortunately none could provide
the data requested.
Study, patients, and treatment characteristics
Overall, 17 studies, carrying out 18 comparisons, were included
in the analyses. Of these, 11 reported data on cetuxi-
mab30–37,41,43 and 6 on panitumumab38–40,42,44,45 (Table T11).
Taken together, all the included RCTs reported data on a total
population of 12,870 patients suffering from: colorectal cancer
(8 studies,30,32,37,39–42 8,931 patients), non-small cell lung can-
cer (3 studies,34,36,38 1,857 patients), gastro-oesophageal cancer
(2 studies,34,44 1,140 patients), squamous cell head and neck
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Figure 2. Risk of bias of included RCTs. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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Table 1. Summary characteristics of the included studies
Study ID
Trial
phase
Underlying
malignancy
Number of
randomized
Safety
population
Treatment
arm A
Treatment
arm B
Anti-EGFR
scheduled
dose1
Median duration
of follow-up
Time-point
of AEs
assemmentarm a arm b arm a arm b
Alberts 201230 3 mCRC 909 954 894 931 mFOLFOX61Cet mFOLFOX6 Cet400mg/m2;
Cet250mg/m2
28 months (0-68) NR
Burtness 200631 3 SCHNC 57 60 58 58 Cisplatin1Cet Cisplatin Cet400mg/m2;
Cet250mg/m2
NR NR
CAIRO232 3 mCRC 368 368 366 366 Capec1Bev1
Cet
Capec1Bev Cet400mg/m2;
Cet250mg/m2
NR NR
Crawford38 2 NSCLC 112 54 112 54 Carboplatin1
Paclitaxel1 Pan
Carboplatin1
Paclitaxel
Pan 6 mg/kg NR NR
EXPAND33 3 Gastric 445 449 446 436 Capec1Cisplatin1
Cet
Capec1Cisplatin Cet400mg/m2;
Cet250mg/m2
20.0–24.9
months
30 days
ALDR
FLEX34 3 NSCLC 557 568 548 562 Cisplatin1
Vinorelbine1Cet
Cisplatin1
Vinorelbine
Cet400mg/m2;
Cet250mg/m2
23.8 months
(22.1–24.9)
Unclear
FOCUS-345 2 mCRC 47 82 47 82 FOLFIRI1Cet FOLFIRI Cet500mg/m2 NR Unclear
Hussain 201435 2 Bladder 60 28 59 28 Gemcit1Cisplatin1
Cet
Gemcit1
Cisplatin
Cet500mg/m2
onday 1 and 15
17.4 vs 14.3 months NR
Kim 201336 3 NSCLC 468 470 451 448 Docetaxel or
pemetrexed1Cet
Docetaxel or
pemetrexed
Cet400mg/m2;
Cet250mg/m2
NR NR
NCCTG N01047
(Huang 2014)37
3 mCRC 40 106 40 106 FOLFIRI1Cet FOLFIRI Cet400mg/m2;
Cet250mg/m2
5.95 years (0.1-7.0) . Unclear
PACCEa39 3b mCRC 413 410 407 397 BevOx1 Pan
(FOLFOX)
BevOx
(FOLFOX)
Pan 6 mg/kg 12.3 monthsfor the
Ox-CT cohort vs 9.0
for the Iri-CT cohort
(0.2 to 26.2)
30 days ALDR
PACCEb39 3b mCRC 115 115 111 113 BevIri1 Pan
(FOLFIRI)
BevIri
(FOLFIRI)
Pan 6 mg/kg 12.3 monthsfor the
Ox-CT cohort vs 9.0
for the Iri-CT cohort
(0.2 to 18.6)
30 days ALDR
Peeters 201040 3 mCRC 591 595 541 542 FOLFIRI1 Pan FOLFIRI Pan 6 mg/kg 13.3 vs 10.2 months
(0.2-31.7 vs 0.5-32.9)
30 days ALDR
PETACC-841 3 mCRC 1280 1279 1149 1179 FOLFOX41Cet FOLFOX4 Cet1,400mg/m2;
Cet250mg/m2
3.3 years (3.2–3.4) 30 days ALDR
PRIME42 3 mCRC 593 590 539 545 FOLFOX41Pan FOLFOX4 Pan 6 mg/kg 80 weeks (0-201) 30 days ALDR
SCOPE-143 3 Esophageal 129 129 129 129 Cisplatin1
Capecitabine1
Radiot1Cet
Cisplatin1
Capecitabine1
Radiot 1
Cet400mg/m2;
Cet250mg/m2
16.8 months
(11.2–24.5)
12 weeks AFA
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cancer (2 studies,33,43 766 patients), bladder cancer (1 study,35
87 patients) and biliary tract cancer (1 study,45 89 patients).
Most used doses were 400 mg/m2 on day one followed by
250 mg/m2 weekly for cetuximab and 6.0 mg/kg every 2 weeks
for panitumumab. Four studies35,41,44,45 reported different
cetuximab and panitumumab doses (Table 1). As the PACCE
trial39 was a multiple arm study reporting results of two differ-
ent treatment comparisons, we considered it as two separate
double-arm studies (PACCEa and PACCEb).
Risk of bias
Most RCTs adopted appropriate methods to generate random
sequences (1530–33,35,36,38–45 out of 17), but fewer reported
appropriate concealment methods (932–34,36,38,41,43–45 out of
17). In one study40 the risk of attrition bias was unclear, but
low in all the others. Due to the open label design all the
studies are at high risk of performance bias, except for one41,
which was designed as double-blind. However, as reported
by the authors, blinding was likely to be compromised by
frequent occurrence of Cetuximab-related skin rashes31. For
the same reason, nine31–33,37,38,41–44 studies are at high risk of
detection bias, and for nine30,34–36,38–40,45,46 the risk is unclear
(Fig. F22).
Incidence and RR of venous thromboembolism
Data on grade 3 and 4 thromboembolic AEs were reported
in all of the included studies. There were 424 cases of venous
thromboembolism out of 6,485 patients in the anti-EGFR
MoAbs group and 283 out of 6,514 patients in the control
group. The weighted mean incidence observed was 7.8%
(95% CI 6.0 to 9.6%) in patients receiving anti-EGFR regi-
mens and 4.6% (95% CI 3.4 to 5.7%) in patients receiving
non-anti-EGFR regimens (Table T22). Using the ﬁxed-effect
model we found that the anti-EGFR regimens were associated
with a higher risk of severe venous thromboembolism
compared with the control arm RR was 1.46 (95% CI 1.27 to
1.69) (I20%, p5 0.83) (Table 2, Fig. F33). NNH, calculated
using the overall RR, is 56 (95% CI 38 to 100).
Incidence and RR of pulmonary embolism
Data on grade 3 and 4 PE events were available for 8 studies
(including 9 comparisons as the four-arm PACCE trial was
considered as two double-arm studies) including a total popu-
lation of 7,028 patients. There were 145 cases of PE out of 3,532
patients in the anti-EGFR MoAbs group and 91 out of 3,496
patients in the control group. The weighted mean incidence
was 3.8% (95% CI 2.3 to 5.3%) in patients receiving anti-EGFR
regimens and 2.7% (95% CI 1.7 to 3.8%) in patients receiving
non-anti-EGFR regimens (Table 2). Using the ﬁxed-effect
model we found that the anti-EGFR-containing regimens were
associated with a higher risk of severe PE compared with the
control arm (RR of 1.55; 95% CI 1.20 to 2.00) (I2 0%, p5 0.99)
(Table 2). NNH, calculated using the overall RR, is 60 CI (95%
CI 33 to 167).
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Subgroups analyses
Tables 2 shows results by anti-EGFR agent used, anti-EGFR
dose and underlying malignancy (Table 2). The effect size
varied, but the differences among subgroups were not statisti-
cally signiﬁcant.
Influence of anti-EGFR scheduled dose on
RR of VTE and PE
We explored whether the use of non-standard schedule of
cetuximab or panitumumab may inﬂuence the risk of throm-
boembolism. We categorized as “standard” the recommended
schedule of 400 mg/m2 initial dose followed by 250 g/m2
weekly for cetuximab and 6 mg/kg bi-weekly for panitumu-
mab. Four studies35,41,44,45 reported different schedules (Table
1). No statistically signiﬁcant difference between subgroups
was found (Supporting Information Appendix). The reported
data did not permit reliable exploration of dose-response
relationship or threshold effect.
Influence of kind of anti-EGFR agent
For the cetuximab trials the average VTE weighted mean inci-
dence was 6.1% (95% CI 4.5 to 7.6%) in patients receiving
cetuximab regimens and 3.7% (95% CI 2.7 to 4.7%) in patients
receiving corresponding regimens without cetuximab. In the
panitumumab subgroup weighted mean incidence was 10.7%
(6.1 to 15.4%) in patients receiving panitumumab regimens
and 6.5% (95% CI 3.3 to 9.6%) in patients receiving the same
regimens minus panitumumab. Using the ﬁxed-effect model
the RR of VTE was 1.46 (95% CI 1.20 to 1.79) in cetuximab
subgroup and 1.46 (95% CI 1.18 to 1.80) in the panitumumab
subgroup (Table 2), with no statistically signiﬁcant difference
between the two subgroups (Fig. 3).
In the cetuximab subgroup we found a PE weighted mean
incidence of 3.8% (95% CI 1.1 to 6.5%) VS 2.3% (95% CI 0.5 to
4.1%) (Table 2). In the panitumumab subgroup the weighted
mean incidence was 4.8% (95% CI 3.2 to 6.5%) VS 2.8% (95%
CI 2.0 to 3.6%). Using the ﬁxed-effect model the RR of PE was
1.60 (95 CI % 1.08 to 2.37) in cetuximab subgroup and 1.51
(95% CI 1.08, 2.13) in the panitumumab subgroup (Table 2).
No statistically signiﬁcant difference between subgroups was
detected (Fig. F44).
Influence of underlying tumour type
Given the potentially differing underlying risks of VTE and PE
among patients with different tumour types, an exploratory analy-
sis stratifying patients by type of malignancy was performed
(Table 2). We found that the majority of the evidence is provided
by studies in colorectal cancer patients. Although effect sizes and
incidences for both VTE and PE were variable, no statistically sig-
niﬁcant differences between types of tumour were observed, Thus
the most reliable estimate of effect is the overall RR 1.45 for VTE
and 1.56 for PE (Table 2; Supporting Information Appendix).
Sensitivity analyses
Sensitivity analyses were carried out to deﬁne whether
co-administration of Bevacizumab might have affected
Table 2. RRs and Mean Weighted Incidences of thromboembolic events
No of Grade 3–4
AEs/total Incidence (CI 95%)
Number of
studies*
Anti-EGFR
arm
Control
arm Anti-EGFR arm Control arm
Relative risk
(CI 95%)
Venous Thromboembolism
Overall 17 424/6,485 283/6,514 7.8% (6.0 to 9.6%) 4.6% (3.4 to 5.7%) 1.46 (1.27 to 1.69)
Cetuximab 10 233/4,360 157/4,414 6.1% (4.5 to 7.6%) 3.7% (2.7 to 4.7%) 1.46 (1.20 to 1.79)
Panitumumab 6 188/2,078 123/2,018 10.7% (6.1 to 15.4%) 6.5% (3.3 to 9.6%) 1.46 (1.18 to 1.80)
Colorectal cancer 7 280/4,424 207/4,507 8.1% (5.3 to 10.8%) 5.5% (3.5 to 7.5%) 1.37 (1.15 to 1.62)
Gastroesophagealcancer 2 41/575 28/565 7.8% (3.3 to 12.3%) 6.0% (0.5 to 11.4%) 1.44 (0.91 to 2.30)
SCHNC 2 27/383 12/383 6.9% (4.3 to 9.4%) 3.1% (1.4 to .4.9%) 2.25 (1.16 to, 4.37)
NSCLC 2 54/952 29/905 6.3% (3.1 to 9.5%) 3.0% (1.6 to 4.4%) 1.61 (1.04 to 2.51)
Bladder cancer 1 17/59 3/28 28.8% (17.3 to 40.4%) 10.7% (0.00 to 22.2%) 2.69 (0.86 to 8.43)
Biliary tract cancer 1 2/45 1/44 4.6% (0 to 10.6%) 2.4% (0 to 6.8%) 1.96 (0.18 to 20.80)
Pulmonary Thromboembolism
Overall 8 145/3,532 91/3,496 3.8% (2.3 to 5.3%) 2.7% (1.7 to 3.8%) 1.55 (1.20 to 2.00)
Cetuximab 3 62/1,779 39/1,803 3.8% (1.1 to 6.5%) 2.3% (0.5 to 4.1%) 1.60 (1.08 to 2.37
Panitumumab 5 83/1,753 52/1,693 4.8% (3.2 to 6.5%) 2.8% (2.0 to 3.6%) 1.51 (1.08, 2.13)
Colorectal cancer 5 86/2,381 55/2,400 4.1% (1.2 to 6.9%) 2.5% (1.2 to 3.8%) 1.57 (1.12 to 2.18)
Gastroesophagealcancer 1 27/446 16/436 6.1% (3.8 to 8.3%) 3.7% (1.9 to 5.4%) 1.65 (0.90 to 3.02)
NSCLC 1 30/660 19/616 4.2% (2.5 to 5.9%) 2.8% (1.5 to 4.2%) 1.47 (0.79 to 2.76)
Biliary tract cancer 1 2/45 1/44 4.6% (0 to 10.6%) 2.4% (0 to 6.8%) 1.96 (0.18 to 20.80)
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heterogeneity. No signiﬁcant change was noted in RR of VTE
and PE (see Supporting Information Appendix).
We also explored clinical heterogeneity by carrying out sensi-
tivity analyses based on imbalance in treatment duration
between two arms of each study, as reported by the authors. We
excluded those RCTs in which a statistically signiﬁcant difference
(p< 0.05) in treatment duration was reported; the results were
consistent with those of the primary analyses (see Supporting
Information Appendix). However, differences in treatment dura-
tion were reported only for a minority of the studies included,
and consequently this analysis remains very uncertain.
Publication bias
We found no obvious evidence of bias related to small study
size, such as publication bias. Visual inspection of funnel plots
for both VTEs and PE (see Supporting Information Appendix)
did not reveal substantial asymmetry, even though only a part
of the potentially eligible studies reported severe thromboem-
bolic events.
Discussion
Cancer-associated thromboembolism is a substantial problem
in clinical practice. It is considered a common, if not the most
common, cause of death in patients with solid tumors.3,4 Drug-
exposure can increase such risk.46
Several mechanisms have been proposed to explain the
hypercoagulable state of cancer patients treated with anticancer
drugs. Experimental studies have indicated that the endothelium
of ﬂuorouracil-treated animals can be badly damaged, resulting
in denudation of underlying structures, with consequential
Figure 4. Overall Relative risk of PE. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 3. Overall Relative risk of VTE. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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platelets accumulation and ﬁbrin formation. Moreover, in
humans exposed to ﬂuorouracil treatment a signiﬁcant increase
in the level of ﬁbrinopeptide A (a substance associated with
hypercoagulable states released from the amino-terminal ends of
ﬁbrinogen) has been reported.47 While it had been demonstrated
that chemotherapy can also induce platelet activation, upregula-
tion of prothrombotic factors and, in particular, endothelial inju-
ry48 the pathogenesis of the thrombotic events associated with
anti-EGFR MoAbs remains unclear, although potential mecha-
nisms can be hypothesized.
The role of EGFR blockade in directly inducing endothelial
damage or increasing thrombogenicity has not been proved.
An enhancement in the expression of plasminogen activator
was observed in vitro in human microvascular endothelial cells
exposed to EGF,49 but it appears more plausible that anti-
EGFR MoAbs could prolong the uncovering of endothelial
structures resulting from co-administered agents, favouring
platelet activation, leukocyte adhesion, oxidative stress, coagu-
lation and inﬂammation, all factors leading to thromboembo-
lism.50 It is well-known that EGF normally act as mitogens
stimulating growth of various populations of cells including the
endothelial ones.51 The blockade of EGFR activation, by either
tyrosine kinase inhibitors or antibodies, causes a dose-
dependent decrease of the angiogenesis related factors VEGF,
Transforming Growth Factor-a (TGF-a), basic Fibroblast
Growth Factor (bFGF), and IL-8 in tumour cells, resulting in
the modulation of angiogenesis.52–55 It seems that EGF may
also affect angiogenesis independently of other angiogenic fac-
tors. Hirata and colleagues inhibited EGF-induced angiogenesis
in vitro by using an EGFR-antagonist, but obtained only a par-
tial inhibition using a VEGFR-inhibitor.56
We sought to comprehensively examine the relationship
between anti-EGFR MoAbs-based regimens and risk of VTEs and
PE in patients with cancer by conducting a systematic review and
combining results from eligible RCTs in a series of meta-analyses.
Based on information from 12,870, patients enrolled in 17
RCTs, we found that those treated with anti-EGFR MoAbs-
containing regimens were approximately 1.5 times more like-
ly to experience VTE or PE, compared to those treated with
the same regimens without anti-EGFR MoAbs. It is notable
that every single trial showed more VTEs and PEs in the
MoAbs arms (as shown by all falling on the right hand side
of the line of equivalence in Figs. 4 andF5 5).
In line with a large meta-analysis of clinical studies57, our
sensitivity analysis, excluding patients receiving anti-VEGFR
MoAb bevacizumab, did not modify the risk of thromboembol-
ic events. Although incidence of VTE and PE varied among
patients with different types of tumours, the impact of anti-
EGFR MoAbs on the relative risk of VTEs and PE did not differ
signiﬁcantly between malignancies. Similarly, we found higher
incidence values in the panitumumab subgroup compared to
the cetuximab subgroup, but RRs were very similar.
It is noteworthy that while in the panitumumab Group 4
comparisons out of 5 are based on metastatic colorectal cancer
patients, in the cetuximab group, more than the half (6 out of
11) of the studies enrolled patients with malignancies other
than colorectal cancer, and only 4 enrolled participants with
metastatic diseases. This condition could be associated with a
higher baseline thromboembolic risk. We found an overall
weighted mean incidence of 10.9% in metastatic cancer patients
receiving cetuximab.
Strengths and limitations
To the best of our knowledge, this is the largest and most-
up-to-date systematic review evaluating the risk of VTEs in
cancer patients and the ﬁrst providing a speciﬁc analysis on
the risk of PE induced by cetuximab and panitumumab. We
took a wider perspective including eleven additional studies
and consequently a larger population than a previously pub-
lished meta-analysis.17 Furthermore, with the aim of reducing
confounding factors, we included only studies where cetuxi-
mab or panitumumab were administered in addition to
exactly the same regimen used in the control arm.
As with other systematic reviews and meta-analyses, there
were differences between included trials in terms of population,
underlying malignancy, intervention, and duration of follow-
up. The risk of bias of the included studies varied from low to
high (Fig. 2). All trials had a high risk of performance and
detection bias related to the lack of blinding (which is usual in
cancer clinical trials). However, this has limited relevance and
impact for the outcomes of interest as grade 3–4 AEs require
medical intervention or hospitalization and are unlikely to be
misdiagnosed. There was no clear evidence of bias related to
small study size, such as publication bias.
It is notable that only a fraction 17 (out of 45) of the other-
wise eligible trials identiﬁed by our searches reported thrombo-
embolic events, such ﬁnding could represent a bias, although it
may be due to the fact that the occurrence of thromboembolic
events was not a primary end-point in RCTs which focused on
effectiveness outcomes, that no such events were observed, or
that authors did not report all the events observed during a
trial. This seems to be the case in at least eleven of the twenty-
nine excluded articles, in which only the most frequent
AEs (with a threshold ranging from 2% to 10%) were reported
(see Supporting Information Appendix).
Patients enrolled into randomized phase II and III trials
meet rigorous eligibility criteria, which exclude many patients
at higher risk for thromboembolism which may have resulted
in a lower incidence of anti-EGFR MoAbs-associated throm-
boembolic events than in the wider cancer population. None-
theless selective underreporting cannot be ruled out.
In conclusion, the additional risk of thromboembolic events
should be taken into account in decision-making. Clinicians
should assess baseline thromboembolic risk58,59 and consider
the additional risk related to the addition of anti-EGFR, taking
into account current evidence60,61 on beneﬁt of antithrombotic
prophylaxis, when deciding whether to add cetuximab or pani-
tumumab to other anti-cancer agents. Prevention of VTE in
cancer patients is a major challenge particularly because of the
potential additional risks relating to use of anti-cancer drugs.
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Further investigation of anti-EGFR MoAb in cancer is
needed to better deﬁne relationships between these agents
and the risk of severe and life-threatening thromboembolism
to develop risk-reduction strategies optimizing the beneﬁt-
harm ratio of anti-EGFR MoAbs.
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